Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: DRUG: MEDI-573|DRUG: Aromatase Inhibitor
Sponsor: MedImmune LLC